Evidence map›Paper›PMID 39390588›Full record

ArticleJournal of biomedical science2024

Secretome from estrogen-responding human placenta-derived mesenchymal stem cells rescues ovarian function and circadian rhythm in mice with cyclophosphamide-induced primary ovarian insufficiency.

Duy-Cuong Le, Mai-Huong T Ngo, Yung-Che Kuo, Shu-Hwa Chen, Chung-Yen Lin, Thai-Yen Ling, Quoc Thao Trang Pham, Heng-Kien Au, Jihwan Myung, Yen-Hua Huang

Abstract read
In one paragraph

Article in Journal of biomedical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Targeting the non-coding RNA-PANoptosis axis: a novel frontier in disease diagnosis and therapy.Apoptosis : an international journal on programmed cell death · 2026
    Review
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Duy-Cuong LeInternational Ph.D. Program in Cell Therapy and Regenerative Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan.
Mai-Huong T NgoDepartment of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, 250 Wuxing Street, Taipei, 11031, Taiwan.
Yung-Che KuoTMU Research Center for Cell Therapy and Regeneration Medicine, Taipei Medical University, 250 Wuxing Street, Taipei, 11031, Taiwan.
Shu-Hwa ChenTMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, 11031, Taiwan.
Chung-Yen LinInstitute of Information Science, Academia Sinica, Taipei, 11529, Taiwan.
Thai-Yen LingDepartment and Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, 10617, Taiwan.
Quoc Thao Trang PhamInternational Ph.D. Program in Cell Therapy and Regenerative Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan.
Heng-Kien AuInternational Ph.D. Program in Cell Therapy and Regenerative Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan. hengkienau@gmail.com.
Jihwan MyungGraduate Institute of Mind, Brain and Consciousness, Taipei Medical University, 250 Wuxing Street, Taipei, 11031, Taiwan. jihwan@tmu.edu.tw.
Yen-Hua HuangInternational Ph.D. Program in Cell Therapy and Regenerative Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan. rita1204@tmu.edu.tw.ORCID http://orcid.org/0000-0001-6020-9998

Funding

National Science and Technology Council 111-2314-B-038-008National Science and Technology Council 112-2314-B-038-063National Science and Technology Council 112-2314-B-038-076National Science and Technology Council NSTC 112-2314-B-038-007Taipei Medical University Hospital 105TMU-TMUH-10
6 · The paper itself

Abstract

backgroundPrimary ovarian insufficiency (POI) is an early decline in ovarian function that leads to ovarian failure. Conventional treatments for POI are inadequate, and treatments based on mesenchymal stem cells (MSCs) have emerged as an option. However, the lack of consideration of the estrogen niche in ovarian tissue significantly reduces the therapeutic efficacy, with an unclear mechanism in the MSCs in POI treatment. Furthermore, the disruption of circadian rhythm associated with POI has not been previously addressed.

methodsConditioned medium (CM) and estradiol-conditioned medium (E2-CM) were generated from estrogen receptor positive MSCs (ER

resultsThe secretome of ER

conclusionThis study is the first to demonstrate that, in considering the estrogen niche in ovarian tissue, an estrogen-priming ER

Indexed as

Circadian RhythmCyclophosphamideMesenchymal Stem CellsMice, Inbred C57BLPrimary Ovarian InsufficiencyAnimalsEstrogensFemaleHumansMiceOvaryPlacentaPregnancySecretomeCyclophosphamideEstrogensAngiogeninEstrogen receptorExosomal miRNAOvarian circadian rhythm disorderPlacenta mesenchymal stem cellPrimary ovarian insufficiency

Identifiers

PMID39390588
PMCPMC11468397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.